Lineage Cell Therapeutics (LCTX) Current Assets (2010 - 2026)

Lineage Cell Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $56.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 12.36% year-over-year to $56.2 million in Q1 2026; TTM through Mar 2026 was $56.2 million, a 12.36% increase from a year earlier, with the FY2025 full-year figure at $59.2 million, up 16.0% from the prior year.
• Current Assets fell to $56.2 million in Q1 2026 per LCTX's latest filing, from $59.2 million in the prior quarter.
• Across five years, Current Assets topped out at $81.9 million in Q1 2022 and bottomed at $34.4 million in Q3 2024.
• The 5-year median for Current Assets is $49.7 million (2023), against an average of $52.2 million.
• Across the five-year window, Current Assets plunged 46.21% in 2022 and surged 32.66% in 2024, its largest moves.
• Year by year, Current Assets stood at $60.0 million in 2022, then slumped by 35.93% to $38.4 million in 2023, then jumped by 32.66% to $51.0 million in 2024, then rose by 16.0% to $59.2 million in 2025, then slipped by 5.06% to $56.2 million in 2026.
• Per Business Quant, the three latest LCTX Current Assets figures stand at $56.2 million (Q1 2026), $59.2 million (Q4 2025), and $42.3 million (Q3 2025).